Komori
Presentation materials for financial results4540TSUMURA & CO.Pharmaceuticals

Supplementary Financial Results Materials for the Fiscal Year Ending March 2026

In FY2025, revenue increased 6.4% year on year, driven in part by the expansion of the China business, while operating income and net income declined. Although revenue fell short of the initial plan, operating income, ordinary income and net income exceeded plan. For FY2026, the company has provided full-year forecasts for higher revenue and operating income, but lower ordinary income and net income.

Worth reading
65In focus
Scored from 5 of 6 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
11521
¥ million
Wording
Conditional
How definitive the wording is.

Contents of this document

Supplementary materials to the earnings reportFiscal year ending March 20265 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥192,615 million+6.4%
Operating profit¥35,219 million-12.2%
Ordinary income¥40,036 million-5.7%
Net income¥28,117 million-13.3%
Gross Profit Margin47.5 %
Operating profit margin18.3 %
Selling, general and administrative expenses¥56,296 million
Results for the three months of the current quarter
FY2025 4Q
Net Sales
¥47,439 million
Operating profit
¥6,357 million
Ordinary income
¥8,128 million
Net income
¥4,966 million
Full-year earnings forecast
Net Sales
¥213,600 million
Operating profit
¥37,500 million
Ordinary income
¥35,500 million
Net income
¥26,200 million
Cost of sales
¥114,700 million
Gross profit
¥98,900 million
Selling, general and administrative expenses
¥61,400 million
Investments and other expenditures
¥50,200 million
Investment in property, plant and equipment
¥46,900 million
Depreciation and amortization
¥13,500 million
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales97.3
Domestic Business Sales96
China business revenue104.5
Cost of sales94.5
Gross profit100.6
Selling, general and administrative expenses100.5
Salaries and allowances98.9
Research and development costs106.1
Operating profit100.6
Domestic business operating profit98.7
Ordinary income116
Net income115.7
Investments and other expenditures84.2
Investment in property, plant and equipment86.2
Depreciation and amortization113.8
What the company explained in this material
Key KPIsA metric the company considers important as a management benchmark.
  • Growth rate by value for 129 prescription medical Kampo formulations-0.1 %
  • Growth rate by volume for 129 prescription medical Kampo formulations0.3 %
  • Number of formulations with value growth61 formulations
    Year on year against the same period last year84 prescriptions in FY2024
Unit price and quantity metricsThese figures show sales broken down by price and volume.
Growth rates by value and volume are shown
Segment results
  • Domestic Business
    Net Sales¥161,172 million
    Year-on-year change in revenue0.4
    Operating profit¥35,024 million
    Year-on-year operating profit growth-12.7
  • China business
    Net Sales¥31,442 million
    Year-on-year change in revenue52.4
    Operating profit¥195 million
    Year-on-year operating profit growthNot comparable
Number of employees
FY20244,233 people
FY20254,923 people
Capital expenditures
¥35,349 million
Contents of this document
ItemDetails
Document typeSupplementary materials to the earnings report
Fiscal Period CoveredFiscal year ending March 2026
Net Sales¥192,615 million (YoY +6.4%)
Operating profit¥35,219 million (YoY -12.2%)
Ordinary income¥40,036 million (YoY -5.7%)
Net income¥28,117 million (YoY -13.3%)
Gross Profit Margin47.5 %
Operating profit margin18.3 %
Selling, general and administrative expenses¥56,296 million
Results for the three months of the current quarterSubject FY2025 4Q / Net Sales ¥47,439 million / Operating profit ¥6,357 million / Ordinary income ¥8,128 million / Net income ¥4,966 million
Full-year earnings forecastNet Sales ¥213,600 million / Operating profit ¥37,500 million / Ordinary income ¥35,500 million / Net income ¥26,200 million / Cost of sales ¥114,700 million / Gross profit ¥98,900 million / Selling, general and administrative expenses ¥61,400 million / Investments and other expenditures ¥50,200 million / Investment in property, plant and equipment ¥46,900 million / Depreciation and amortization ¥13,500 million
Progress against full-year forecastNet Sales 97.3 / Domestic Business Sales 96 / China business revenue 104.5 / Cost of sales 94.5 / Gross profit 100.6 / Selling, general and administrative expenses 100.5 / Salaries and allowances 98.9 / Research and development costs 106.1 / Operating profit 100.6 / Domestic business operating profit 98.7 / Ordinary income 116 / Net income 115.7 / Investments and other expenditures 84.2 / Investment in property, plant and equipment 86.2 / Depreciation and amortization 113.8
Segment resultsSegment Domestic Business / Net Sales ¥161,172 million / Year-on-year change in revenue 0.4 / Operating profit ¥35,024 million / Year-on-year operating profit growth -12.7, Segment China business / Net Sales ¥31,442 million / Year-on-year change in revenue 52.4 / Operating profit ¥195 million / Year-on-year operating profit growth Not comparable
Key KPIs-0.1 %, 0.3 %, 61 formulations
Unit price and quantity metricsGrowth rates by value and volume are shown
Number of employeesFY2024 4,233 people / FY2025 4,923 people
Capital expenditures¥35,349 million
Items this document does not state (14)
Self-assessment against the planBreakdown of Factors Affecting the ChangeNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&ANew initiatives

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The document does not explain the factors behind the increases or decreases in results. It states that, for 上海虹橋中薬飲片有限公司, the balance sheet was consolidated from the second quarter of the fiscal year ending March 2026, the income statement from the third quarter, and the PPA was finalized in the fourth quarter.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Supplementary Financial Results Materials for the Fiscal Year Ending March 2026 | TSUMURA & CO. (4540) timely disclosure | Komori